US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bicara Therapeutics

14.97

+0.16001.08%

Volume:105.86K

Turnover:1.52M

Market Cap:816.21M

PE:-3.70

High:15.09

Open:14.71

Low:13.80

Close:14.81

Loading ...

Overview Company News Filings

Bicara Therapeutics Initiated at Outperform by Wedbush

Wedbush Initiates Coverage on Bicara Therapeutics With Outperform, $31 Price Target

MT Newswires Live

Bicara Therapeutics initiated with an Outperform at Wedbush

Bicara Therapeutics Inc : Wedbush Initiates Coverage With Outperform Rating; Target Price $31

THOMSON REUTERS

Promising Clinical Trial Results Drive Buy Rating for Bicara Therapeutics

Bicara presents data from Phase 1/1b dose expansion cohort of ficerafusp alfa

Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium

Bicara Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Stifel Nicolaus Sticks to Their Buy Rating for Bicara Therapeutics Inc. (BCAX)

Third Rock-backed Maze Therapeutics reveals profit in US IPO filing

Bicara Therapeutics Initiated at Buy by HC Wainwright & Co.

Bicara Therapeutics Inc : H.c. Wainwright Initiates Coverage With Buy Rating; Target Price $42

THOMSON REUTERS

Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa: A Buy Rating Supported by Innovative Dual-Targeting and Positive Trial Results

Bicara Therapeutics initiated with a Not Rated at Goldman Sachs

Bicara Therapeutics Reports Strong IPO and Clinical Advancements

Stifel Nicolaus Remains a Buy on Bicara Therapeutics Inc. (BCAX)

Promising Prospects for Bicara Therapeutics: Buy Rating Reinforced by Strong Lead Asset and Strategic Position

Promising Prospects for Bicara Therapeutics: Buy Rating on Ficerafusp’s Innovative Approach

Bicara Therapeutics Q3 2024 GAAP EPS $(1.60) Misses $(0.44) Estimate

Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BCAX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BCAX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","market":"US","secType":"STK","nameCN":"Bicara Therapeutics","latestPrice":14.97,"timestamp":1745941898498,"preClose":14.81,"halted":0,"volume":105858,"delay":0,"floatShares":28372221,"shares":54523326,"eps":-4.045991,"marketStatus":"Trading","change":0.16,"latestTime":"04-29 11:52:10 EDT","open":14.71,"high":15.0903,"low":13.8,"amount":1515008.99718,"amplitude":0.087124,"askPrice":15.14,"askSize":26,"bidPrice":14.85,"bidSize":2,"shortable":3,"etf":0,"ttmEps":-4.045991,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745956800000},"marketStatusCode":2,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":14.81,"preHourTrading":{"tag":"盘前","latestPrice":14.81,"preClose":14.81,"latestTime":"09:29 EDT","volume":10,"amount":148.28,"timestamp":1745933370072},"postHourTrading":{"tag":"盘后","latestPrice":14.81,"preClose":14.81,"latestTime":"16:05 EDT","volume":1146,"amount":16972.26,"timestamp":1745870706681},"volumeRatio":0.475836,"impliedVol":0.5541,"impliedVolPercentile":0.3629},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","floatShares":28372221,"roa":"-13.84%","roe":"-19.14%","lyrEps":-4.045991,"volumeRatio":0.475836,"shares":54523326,"dividePrice":0,"high":15.0903,"amplitude":0.087124,"preClose":14.81,"low":13.8,"week52Low":8.91,"pbRate":"1.66","week52High":28.09,"institutionHeld":0,"latestPrice":14.97,"committee":-0.857143,"eps":-4.045991,"divideRate":0,"volume":105858,"delay":0,"ttmEps":-4.045991,"open":14.71,"prevYearClose":17.42,"prevWeekClose":14.54,"prevMonthClose":13.03,"prevQuarterClose":13.03,"fiveDayClose":13.82,"twentyDayClose":13.03,"sixtyDayClose":12.62},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BCAX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2509946276","title":"Bicara Therapeutics Initiated at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2509946276","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509946276?lang=en_us&edition=fundamental","pubTime":"2025-02-06 21:44","pubTimestamp":1738849440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 06, 2025 08:44 ET (13:44 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX"],"gpt_icon":0},{"id":"2509043278","title":"Wedbush Initiates Coverage on Bicara Therapeutics With Outperform, $31 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2509043278","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509043278?lang=en_us&edition=fundamental","pubTime":"2025-02-06 21:00","pubTimestamp":1738846822,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics (BCAX) has an average rating of Buy and mean price target of $41.40, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCAX"],"gpt_icon":0},{"id":"2509922887","title":"Bicara Therapeutics initiated with an Outperform at Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2509922887","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509922887?lang=en_us&edition=fundamental","pubTime":"2025-02-06 18:00","pubTimestamp":1738836057,"startTime":"0","endTime":"0","summary":"Wedbush analyst David Nierengarten last night initiated coverage of Bicara Therapeutics (BCAX) with an Outperform rating and $31 price target The f...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-initiated-with-an-outperform-at-wedbush-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-initiated-with-an-outperform-at-wedbush-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX"],"gpt_icon":0},{"id":"2509944002","title":"Bicara Therapeutics Inc : Wedbush Initiates Coverage With Outperform Rating; Target Price $31","url":"https://stock-news.laohu8.com/highlight/detail?id=2509944002","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509944002?lang=en_us&edition=fundamental","pubTime":"2025-02-06 11:53","pubTimestamp":1738813997,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250206:nFWN3OW1QS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2506594840","title":"Promising Clinical Trial Results Drive Buy Rating for Bicara Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2506594840","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506594840?lang=en_us&edition=fundamental","pubTime":"2025-01-28 19:17","pubTimestamp":1738063033,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Judah Frommer from Morgan Stanley maintained a Buy rating on Bicara Therapeutics Inc. (BCAX – Research Report), wit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-clinical-trial-results-drive-buy-rating-for-bicara-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-clinical-trial-results-drive-buy-rating-for-bicara-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX"],"gpt_icon":0},{"id":"2506722374","title":"Bicara presents data from Phase 1/1b dose expansion cohort of ficerafusp alfa","url":"https://stock-news.laohu8.com/highlight/detail?id=2506722374","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506722374?lang=en_us&edition=fundamental","pubTime":"2025-01-27 21:15","pubTimestamp":1737983753,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics (BCAX) announced the presentation of data from the Phase 1/1b dose expansion cohort of ficerafusp alfa in combination with pemb...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bicara-presents-data-from-phase-1-1b-dose-expansion-cohort-of-ficerafusp-alfa?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bicara-presents-data-from-phase-1-1b-dose-expansion-cohort-of-ficerafusp-alfa?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2506741083","title":"Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2506741083","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506741083?lang=en_us&edition=fundamental","pubTime":"2025-01-27 21:00","pubTimestamp":1737982800,"startTime":"0","endTime":"0","summary":"BOSTON, Jan.  27, 2025  (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/27/3015540/0/en/Bicara-Therapeutics-Presents-Phase-1-1b-Dose-Expansion-Results-with-Ficerafusp-Alfa-in-Advanced-Squamous-Cancer-of-the-Anal-Canal-at-the-2025-ASCO-Gastrointestinal-Cancers-Symposiu.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","PFS","IE00B66KJ199.SGD","IE0031619046.USD","BK4195","AEIS","IE00B19Z4B17.USD","PR","IE00B7SZL793.SGD","BCAX","BK4139","BK4211","BK4157"],"gpt_icon":0},{"id":"2506374088","title":"Bicara Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2506374088","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506374088?lang=en_us&edition=fundamental","pubTime":"2025-01-27 21:00","pubTimestamp":1737982800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 27, 2025 08:00 ET (13:00 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX"],"gpt_icon":0},{"id":"2506371246","title":"Stifel Nicolaus Sticks to Their Buy Rating for Bicara Therapeutics Inc. (BCAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2506371246","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506371246?lang=en_us&edition=fundamental","pubTime":"2025-01-27 20:45","pubTimestamp":1737981911,"startTime":"0","endTime":"0","summary":"In a report released today, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Bicara Therapeutics Inc. (BCAX – Research Report). The c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-their-buy-rating-for-bicara-therapeutics-inc-bcax-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-their-buy-rating-for-bicara-therapeutics-inc-bcax-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","BCAX"],"gpt_icon":0},{"id":"2501751583","title":"Third Rock-backed Maze Therapeutics reveals profit in US IPO filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2501751583","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501751583?lang=en_us&edition=fundamental","pubTime":"2025-01-08 06:57","pubTimestamp":1736290652,"startTime":"0","endTime":"0","summary":"Third Rock-backed Maze Therapeutics reveals profit in US IPO filing Jan 7 (Reuters) - Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nL4N3O31NX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEPN","BK4207","BK4211","BK4007","BK4588","BCAX","BK4139","SIVBQ","BK4585","BK4589"],"gpt_icon":0},{"id":"2489625989","title":"Bicara Therapeutics Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2489625989","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489625989?lang=en_us&edition=fundamental","pubTime":"2024-12-07 01:34","pubTimestamp":1733506440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 06, 2024 12:34 ET (17:34 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2489228068","title":"Bicara Therapeutics Inc : H.c. Wainwright Initiates Coverage With Buy Rating; Target Price $42","url":"https://stock-news.laohu8.com/highlight/detail?id=2489228068","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489228068?lang=en_us&edition=fundamental","pubTime":"2024-12-06 21:18","pubTimestamp":1733491096,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241206:nFWN3N719K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2489280633","title":"Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa: A Buy Rating Supported by Innovative Dual-Targeting and Positive Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2489280633","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489280633?lang=en_us&edition=fundamental","pubTime":"2024-12-06 21:15","pubTimestamp":1733490934,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics Inc. (BCAX) has received a new Buy rating, initiated by H.C. Wainwright analyst, Robert Burns. Robert Burns has given his Buy r...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-potential-of-bicara-therapeutics-ficerafusp-alfa-a-buy-rating-supported-by-innovative-dual-targeting-and-positive-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-potential-of-bicara-therapeutics-ficerafusp-alfa-a-buy-rating-supported-by-innovative-dual-targeting-and-positive-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX"],"gpt_icon":0},{"id":"2485179391","title":"Bicara Therapeutics initiated with a Not Rated at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2485179391","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485179391?lang=en_us&edition=fundamental","pubTime":"2024-11-21 05:45","pubTimestamp":1732139119,"startTime":"0","endTime":"0","summary":"Goldman Sachs initiated coverage of Bicara Therapeutics (BCAX) with a Not Rated, saying ficerafusp could beat pembro in first-line HPV-negative hea...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-initiated-with-a-not-rated-at-goldman-sachs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-initiated-with-a-not-rated-at-goldman-sachs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B19Z3B42.SGD","BK4550","IE0004091025.USD","LU2237438978.USD","LU2237443978.SGD","LU1791807156.HKD","BCAX","IE00B19Z3581.USD","LU2237443382.USD","LU2237443549.SGD","LU1668664300.SGD","IE0034235188.USD","BK4585","BK4552","IE00BSNM7G36.USD","BK4533","IE00BFXG1179.USD","LU2237443622.USD","IE0002270589.USD","BK4139","LU2237443465.HKD","BK4588","BK4516","BK4127","LU2237443895.HKD","BK4504","IE0004086264.USD","LU0106831901.USD"],"gpt_icon":0},{"id":"2483189022","title":"Bicara Therapeutics Reports Strong IPO and Clinical Advancements","url":"https://stock-news.laohu8.com/highlight/detail?id=2483189022","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483189022?lang=en_us&edition=fundamental","pubTime":"2024-11-14 12:43","pubTimestamp":1731559384,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics Inc. ( ($BCAX) ) has released its Q3 earnings. Here is a breakdown of the information Bicara Therapeutics Inc. presented to its...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bicara-therapeutics-reports-strong-ipo-and-clinical-advancements?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bicara-therapeutics-reports-strong-ipo-and-clinical-advancements?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2483008100","title":"Stifel Nicolaus Remains a Buy on Bicara Therapeutics Inc. (BCAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483008100","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483008100?lang=en_us&edition=fundamental","pubTime":"2024-11-13 21:17","pubTimestamp":1731503844,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Bicara Therapeutics Inc. (BCAX – Research Report) today. The company’s shares clo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-remains-a-buy-on-bicara-therapeutics-inc-bcax?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-remains-a-buy-on-bicara-therapeutics-inc-bcax?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4127","SF","BCAX"],"gpt_icon":0},{"id":"2483096200","title":"Promising Prospects for Bicara Therapeutics: Buy Rating Reinforced by Strong Lead Asset and Strategic Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2483096200","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483096200?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:15","pubTimestamp":1731500117,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Judah Frommer has maintained their bullish stance on BCAX stock, giving a Buy rating yesterday. Judah Frommer’s rating is ba...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-prospects-for-bicara-therapeutics-buy-rating-reinforced-by-strong-lead-asset-and-strategic-position?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-prospects-for-bicara-therapeutics-buy-rating-reinforced-by-strong-lead-asset-and-strategic-position?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX"],"gpt_icon":0},{"id":"2483558770","title":"Promising Prospects for Bicara Therapeutics: Buy Rating on Ficerafusp’s Innovative Approach","url":"https://stock-news.laohu8.com/highlight/detail?id=2483558770","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483558770?lang=en_us&edition=fundamental","pubTime":"2024-11-13 03:35","pubTimestamp":1731440148,"startTime":"0","endTime":"0","summary":"Tyler Van Buren, an analyst from TD Cowen, has initiated a new Buy rating on Bicara Therapeutics Inc. (BCAX). Tyler Van Buren has given his Buy rat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-prospects-for-bicara-therapeutics-buy-rating-on-ficerafusps-innovative-approach?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-prospects-for-bicara-therapeutics-buy-rating-on-ficerafusps-innovative-approach?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX"],"gpt_icon":0},{"id":"2482470612","title":"Bicara Therapeutics Q3 2024 GAAP EPS $(1.60) Misses $(0.44) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2482470612","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482470612?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:47","pubTimestamp":1731415676,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(1.60) per share which missed the analyst consensus estimate of $(0.44) by 263.64 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41898061/bicara-therapeutics-q3-2024-gaap-eps-1-60-misses-0-44-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Bicara Therapeutics Q3 2024 GAAP EPS $(1.60) Misses $(0.44) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX"],"gpt_icon":0},{"id":"2482707763","title":"Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2482707763","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482707763?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:01","pubTimestamp":1731358860,"startTime":"0","endTime":"0","summary":"BOSTON, Nov.  11, 2024  (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/11/2978554/0/en/Bicara-Therapeutics-to-Present-at-the-Stifel-2024-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4127","BK4137","BCAX","SF","HCSG"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":40,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BCAX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-27","symbol":"BCAX","fiscalQuarterEnding":"2024/12","expectedEps":-0.31,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"pre","actualEps":-0.39},{"market":"US","date":"2024-11-12","symbol":"BCAX","fiscalQuarterEnding":"2024/09","expectedEps":-0.46,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.6}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BCAX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BCAX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2857,"buy":0.5714,"hold":0,"sell":0.1429,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":7,"updateTime":1745121600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BCAX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BCAX","date":"2025-04-25","current":-12.533268,"percent":0.588235,"low":-22.704836,"twenty":-19.02049,"median":-15.045308,"eighty":-11.297018,"high":-7.513546,"avg":-15.029169,"sd":3.978013,"marketCap":852199585},"quantilePoints":[{"date":"2024-09-13","current":-12.837909,"twenty":-12.837909,"median":-12.837909,"eighty":-12.837909,"marketCap":832435719},{"date":"2024-09-20","current":-20.633135,"twenty":-21.391361,"median":-20.283845,"eighty":-14.007791,"marketCap":1337893755},{"date":"2024-09-27","current":-21.555755,"twenty":-21.594337,"median":-21.446718,"eighty":-19.006626,"marketCap":1397718272},{"date":"2024-10-04","current":-19.962139,"twenty":-21.575885,"median":-21.337681,"eighty":-19.559541,"marketCap":1294385015},{"date":"2024-10-11","current":-15.936161,"twenty":-21.540658,"median":-20.570229,"eighty":-18.732598,"marketCap":1033332575},{"date":"2024-10-18","current":-17.143955,"twenty":-21.466848,"median":-20.283845,"eighty":-16.808457,"marketCap":1111648307},{"date":"2024-10-25","current":-18.964032,"twenty":-21.403103,"median":-19.23243,"eighty":-16.959431,"marketCap":1229665764},{"date":"2024-10-31","current":-19.878264,"twenty":-21.362844,"median":-19.23243,"eighty":-17.02653,"marketCap":1288946422},{"date":"2024-11-08","current":-19.79439,"twenty":-21.337681,"median":-19.82794,"eighty":-17.143955,"marketCap":1283507830},{"date":"2024-11-15","current":-20.345116,"twenty":-21.127995,"median":-19.949558,"eighty":-18.418848,"marketCap":1210086831},{"date":"2024-11-22","current":-16.257533,"twenty":-21.102833,"median":-19.82794,"eighty":-17.143955,"marketCap":966965549},{"date":"2024-11-29","current":-19.02049,"twenty":-20.975343,"median":-19.458892,"eighty":-17.009755,"marketCap":1131300719},{"date":"2024-12-06","current":-17.876882,"twenty":-20.695202,"median":-19.01323,"eighty":-17.12047,"marketCap":1063281195},{"date":"2024-12-13","current":-16.509127,"twenty":-20.532485,"median":-19.005969,"eighty":-17.12047,"marketCap":981929844},{"date":"2024-12-20","current":-15.187116,"twenty":-20.493904,"median":-18.892739,"eighty":-16.769874,"marketCap":903299275},{"date":"2024-12-27","current":-17.49263,"twenty":-20.458153,"median":-18.854995,"eighty":-16.764842,"marketCap":1040426635},{"date":"2025-01-03","current":-15.484454,"twenty":-20.399979,"median":-18.727694,"eighty":-16.641786,"marketCap":920984351},{"date":"2025-01-10","current":-13.952019,"twenty":-20.332862,"median":-18.565256,"eighty":-16.325863,"marketCap":829838189},{"date":"2025-01-17","current":-10.868852,"twenty":-20.271506,"median":-18.306879,"eighty":-15.951961,"marketCap":646457553},{"date":"2025-01-24","current":-10.951191,"twenty":-20.22215,"median":-18.224539,"eighty":-15.55307,"marketCap":651354959},{"date":"2025-01-31","current":-11.811185,"twenty":-20.138275,"median":-17.666458,"eighty":-14.949245,"marketCap":702505641},{"date":"2025-02-07","current":-11.52757,"twenty":-20.11652,"median":-17.561246,"eighty":-13.156068,"marketCap":685636799},{"date":"2025-02-14","current":-12.003311,"twenty":-19.978914,"median":-17.49263,"eighty":-12.003311,"marketCap":713932921},{"date":"2025-02-21","current":-12.643731,"twenty":-19.965494,"median":-17.085242,"eighty":-11.997822,"marketCap":752023854},{"date":"2025-02-28","current":-11.307997,"twenty":-19.942009,"median":-16.815614,"eighty":-11.891694,"marketCap":672577050},{"date":"2025-03-07","current":-14.409462,"twenty":-19.890007,"median":-16.73236,"eighty":-11.891694,"marketCap":857045999},{"date":"2025-03-14","current":-12.213735,"twenty":-19.838005,"median":-16.60519,"eighty":-11.893524,"marketCap":726448513},{"date":"2025-03-21","current":-11.975864,"twenty":-19.8011,"median":-16.394587,"eighty":-11.882546,"marketCap":712300452},{"date":"2025-03-28","current":-10.745093,"twenty":-19.525992,"median":-16.092853,"eighty":-11.882546,"marketCap":730612568},{"date":"2025-04-04","current":-9.486153,"twenty":-19.364339,"median":-15.936742,"eighty":-11.721526,"marketCap":645010946},{"date":"2025-04-11","current":-8.139007,"twenty":-19.311424,"median":-15.55307,"eighty":-11.500123,"marketCap":553411758},{"date":"2025-04-17","current":-9.430022,"twenty":-19.133936,"median":-15.269456,"eighty":-11.355571,"marketCap":641194313},{"date":"2025-04-25","current":-12.533268,"twenty":-19.02049,"median":-15.045308,"eighty":-11.297018,"marketCap":852199585}],"updateTime":1745909291425}}}